Pharvaris, pushing through trial pause, sees shares surge with new study results

Though the FDA halted testing of the biotech’s pill for HAE in August, enough patients were already enrolled to accrue results that sent shares soaring. Shares of Swiss biotechnology company Pharvaris more than quadrupled Thursday after one of its experimental drugs was able to reduce symptoms of a rare swelling disorder in a mid-stage trial. Discover more…